MCAC Panel Recommends Medicare Coverage For Stem Cell Therapy
This article was originally published in The Gray Sheet
Executive Summary
Autologous stem cell transplantation (ASCT) in combination with high dose chemotherapy should receive Medicare coverage for treatment of multiple myeloma, the Drugs, Biologics and Therapeutics Panel of the Medicare Coverage Advisory Committee unanimously recommended Sept. 16 in a 5-0 vote.